Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
Site Search
Showing 11 - 20 of 97 results
News
|
|
4 min read
Yesterday, President Donald J. Trump signed the Right to Try bill into law. The House approved the bill last week and the Senate passed it last summer.
News
|
|
3 min read
News
|
|
1 min read
News
|
|
1 min read
News
|
|
2 min read
News
|
|
1 min read
The Cystic Fibrosis Foundation recently signed on to a letter with more than 70 organizations in opposition to the Right to Try Act, which passed in the House of Representatives earlier this month.
News
|
|
3 min read
News
|
|
1 min read
News
|
|
2 min read
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
News
|
|
3 min read